Peking University-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2023

  1. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

    Leukemia, Vol. 37, Núm. 7, pp. 1511-1520

2022

  1. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy

    Kidney International, Vol. 102, Núm. 1, pp. 160-172

  2. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

2021

  1. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

    Journal of the American Society of Nephrology, Vol. 32, Núm. 2

2020

  1. Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool

    Kidney International, Vol. 98, Núm. 4, pp. 1009-1019

2018

  1. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    British Journal of Haematology, Vol. 183, Núm. 3, pp. 411-420

2017

  1. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

    Leukemia and Lymphoma, Vol. 58, Núm. 1, pp. 153-161

  2. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant

    Haematologica, Vol. 102, Núm. 2, pp. 401-410

2016

  1. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: Rationale for further study on blood pressure targets of antihypertensive treatment after stroke

    Journal of Hypertension, Vol. 34, Núm. 3, pp. 393-396

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1888-1897

  2. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1741-1750

  3. Residual macrovascular risk in 2013: What have we learned?

    Cardiovascular Diabetology, Vol. 13, Núm. 1